Tidal ETF Trust
Stock Promoter Performance
Last 4 Stock Promotions By "Tip"
|INND||Innerscope Hearing Technologies, Inc.||October 17, 2021||0.0089||-2%|
|IWBB||Iweb Inc.||October 10, 2021||2.45||-2%|
|LQWDF||LQwD FinTech Corp.||October 3, 2021||0.287||-5%|
|AVCRF||Avricore Health Inc.||September 26, 2021||0.128||2%|
TRYP Promotional Newsletter
The following is a newsletter released by "Tip" promoting Tidal ETF Trust
Tryp Therapeutics Inc. CSE OTCQB is leading the next wave of psychedelic drug development beyond mental health with its focus on psilocybin-based treatments for chronic pain and other indications. The company was founded in 2019 and is headquartered in San Diego, California.
Innovative Drug Pipeline
Tryps Psilocybin-for-Neuropsychiatric Disorders PFN program is focused on the development of synthetic psilocybin for chronic pain and other indications.
The company has announced plans to initiate four upcoming Phase 2a clinical trials in fibromyalgia, phantom limb pain, complex regional pain syndrome CRPS, and certain overeating disorders binge eating disorder and hypothalamic obesity. At least two of the Phase 2a studies are expected to begin enrolling patients in 2021.
The companys development plans cover three strategic initiatives
Innovate Tryp is using its unique drug products to pursue chronic pain and other indications that most other psychedelic companies are not through collaborations with leading academic institutions such as the University of Michigan, the University of Florida, and others.
Develop Tryp intends to utilize the FDAs 505b2 regulatory pathway with available third-party preclinical data to shorten the timelines and lower the cost of its development programs.
Protect Tryp plans to utilize regulatory exclusivity, patents, trade secrets and proprietary know-how to protect the commercial lifespan of its drug candidates.
October 21, 2021 1230 PM
Tryp announced its inclusion in the AdvisorShares Psychedelics ETF
The company hopes that its participation will open it up to a more diverse shareholder base and broaden its life science exposure
Tryps presentation at the KCSA Virtual Investor Conference will also be available for on-demand viewing over the next 90 days
Launched back in September 2021, the AdvisorShares Psychedelics Exchange-Traded Fund ETF has been actively trading, focusing on enterprises that have devoted a significant proportion of their assets to psychedelic drug development. Operating under the ticker symbol PSIL on the New York Stock Exchange NYSE Arca exchange, this fund has built a portfolio that includes over 25 different psychedelic companies. is the latest addition to that group.
Other companies we are watching
Tip Us Off
Know of a stock poised to make a big move Tell us which one and why We're constantly scanning the headlines and keeping tabs on what's hot, but can always use an extra hand. Whether amateur or pro, you're more than welcome to join in on the fun
Sign Up For Instant Alerts
Micro-cap stocks can make rapid moves of 50% or more, making the latest information extremely critical to maximizing profits.
Please read for FULL Compensation Disclosures and other disclaimers.
Get Every Penny Stock Alert!
OTC Dynamics tracks all penny stock promotions. Become a member today and never miss another penny stock promotion!
OTC Dynamics is not affiliated with the company being promoted or the associated stock promoter.
The information on this page is not a recommendation to buy or sell securities.